Zurich Cantonal Bank
ASND icon

Zurich Cantonal Bank’s Ascendis Pharma A/S ASND Stock Holding History

Zurich Cantonal Bank’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56
Closed -$11.9K – 2637
2025
Q4 		$11.9K Buy
+56
New +$11.6K ﹤0.01% 2478

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Zurich Cantonal Bank's ASND Position: Q4 2025 in Review

Zurich Cantonal Bank sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 56 shares — an estimated $11.6K sold.

Zurich Cantonal Bank first reported a position in ASND in Q4 2019 and held it in 22 quarters. The position peaked at $807K in Q4 2020. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

  • Zurich Cantonal Bank reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 56 Ascendis Pharma A/S shares in Q4 2025, an estimated $11.6K.
  • Zurich Cantonal Bank first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 22 quarters.
  • Zurich Cantonal Bank's Ascendis Pharma A/S position peaked at $807K in Q4 2020.
  • 302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Zurich Cantonal Bank's 13F filing for Q4 2025, filed 27 Jan 2026.